GLP-1-based therapies and in particular GLP-1 receptor agonists have proven to be effective in lowering blood glucose and decreasing weight in type 2 diabetes mellitus and obesity patients (Cai et al., 2017). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.